Cosmo shares buoyed by successful antibiotic data

Shares of Italy's Cosmo Pharmaceuticals were buoyed by news of positive preliminary data from a Phase II/III trial of Rifamycin for infectious diarrhea. The antibiotic hit its primary goal of the time from taking a dose to the last unformed stool. Analysts immediately leaped on the news, citing the likelihood that the company would soon take several strides forward on its development. Lehman Brothers pegged potential annual sales at $120 million.

"We believe these positive data could now enable the product to be partnered in Europe and filed in selected European countries," said Lehman Brothers. "In addition, Cosmo will now likely commence a Phase III study for U.S. regulatory filing."

- see the release
- here's the AFX report for more data

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.